Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

MindRank’s MDR-001 Phase IIb Study Achieves Clinical Endpoints for Weight Loss

Fineline Cube Jun 20, 2025

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced that the multi-center, 24-week Phase IIb...

Company Drug

Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China

Fineline Cube Jun 19, 2025

Sino-US firm Eccogene Inc., a partner of UK major AstraZeneca (AZ, NASDAQ: AZN), announced the...

Company Drug

Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma

Fineline Cube Jun 19, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...

Drug Medical Device Policy / Regulatory

FDA Launches ‘Elsa’ AI Tool to Enhance Staff Efficiency in Regulatory Processes

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) announced the launch of an artificial intelligence (AI)...

Drug Policy / Regulatory

FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...

Company Drug

Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP

Fineline Cube Jun 19, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the...

Company Drug

Fosun Pharma’s Fumaining Launches Clinically for Rare Disease Treatment in China

Fineline Cube Jun 19, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd.’s (HKG: 2196, SHA: 600196) in-house developed Category 1 drug...

Drug Policy / Regulatory

FDA Launches Commissioner’s National Priority Voucher Program for Accelerated Drug Reviews

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) this week announced the launch of the Commissioner’s...

Company Drug

Hengrui Pharma’s Ruitanning Enters Clinical Use for Chemo-Induced Nausea and Vomiting

Fineline Cube Jun 19, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the prescription of its Category 1...

Company Drug

Merck’s Clesrovimab Gears Up for Priority Review in China for RSV Prevention

Fineline Cube Jun 19, 2025

China’s Center for Drug Evaluation (CDE) website indicates that US giant Merck, Sharp & Dohme’s...

Company Drug

Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes

Fineline Cube Jun 18, 2025

Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of...

Company Medical Device

Allgens Medical’s SkuHeal Artificial Bone Repair Material Gains Vietnam Marketing Approval

Fineline Cube Jun 18, 2025

Beijing-based regenerative medicine materials and implantable device maker Allgens Medical Technology Co., Ltd (SHA: 688613)...

Company Drug

Clover Biopharmaceuticals Completes Enrollment for Phase I Trial of RSV + hMPV Combination Vaccines

Fineline Cube Jun 18, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the completion of enrollment for the first participants...

Company Deals

Shanghai Henlius Biotech Partners with Shanghai Chest Hospital for Clinical Research and Talent Development

Fineline Cube Jun 18, 2025

China’s Shanghai Henlius Biotech Inc., (HKG: 2696) this week entered into a strategic collaboration agreement...

Company Drug

RemeGen’s Telitacicept Receives Orphan Drug Designation for Myasthenia Gravis in Europe

Fineline Cube Jun 18, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced that it has received orphan drug...

Company Drug

Yunnan Baiyao’s JZ-14 Gets NMPA Clinical Clearance for Ulcerative Colitis Trial

Fineline Cube Jun 18, 2025

Kunming-based Yunnan Baiyao Group Co., Ltd (SHE: 000538), traditionally known for Chinese medicine, announced clinical...

Company Drug

Johnson & Johnson Submits sBLA to Expand Stelara Use for Pediatric Crohn’s Disease

Fineline Cube Jun 18, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) this week submitted a supplemental Biologics License...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG005 and ZG006 Combination Trial in Advanced Cancers

Fineline Cube Jun 18, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Medical Device

Mindray Bio-Medical Expands North American Warehouse to Enhance Operational Efficiency

Fineline Cube Jun 18, 2025

China-based Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) announced the groundbreaking of its North...

Company

GSK Launches ‘Linked by Lupus’ Initiative to Support Lupus Care with $1M Funding

Fineline Cube Jun 18, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the launch of the Linked by Lupus:...

Posts pagination

1 … 141 142 143 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.